Matrix metalloproteinases: Difference between revisions
Tzvia Selzer (talk | contribs) No edit summary |
No edit summary |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{STRUCTURE_2clt| PDB=2clt | SIZE=300| SCENE=Matrix_metalloproteinase/Cv/1 |right| CAPTION= Human MMP1 complex with Ca+2 and Zn+2 ions, [[2clt]] }} | |||
== Endopeptidases involved in the degradation of the extracellular matrix== | == Endopeptidases involved in the degradation of the extracellular matrix== | ||
The matrix metalloproteinases (MMPs) are zinc- and calcium dependent neutral endopeptidases involved in the degradation of the extracellular matrix and in tissue remodeling. Currently, approximately 27 MMPs are known. These have been grouped into subfamilies on the basis of their substrate specificity. Transcriptional regulation, zymogen activation and endogenous inhibitors control MMP activity under normal physiological conditions. Disturbance of this physiological balance may lead to an overexpression of MMPs followed by accelerated matrix degradation. The latter is associated with several pathologies including cancer cell invasion and metastasis, the loss of cartilage in osteoarthritis, rheumatoid arthritis, cardiovascular diseases, acute lung injury, chronic obstructive pulmonary disease, eye and skin diseases and periodontitis. As a consequence, the MMP family has emerged as an attractive pharmaceutical target. | The matrix [[metalloproteases|metalloproteinases]] (MMPs) are zinc- and calcium dependent neutral endopeptidases involved in the degradation of the extracellular matrix and in tissue remodeling. Currently, approximately 27 MMPs are known. These have been grouped into subfamilies on the basis of their substrate specificity. Transcriptional regulation, zymogen activation and endogenous inhibitors control MMP activity under normal physiological conditions. Disturbance of this physiological balance may lead to an overexpression of MMPs followed by accelerated matrix degradation. The latter is associated with several pathologies including cancer cell invasion and metastasis, the loss of cartilage in osteoarthritis, rheumatoid arthritis, cardiovascular diseases, acute lung injury, chronic obstructive pulmonary disease, eye and skin diseases and periodontitis.<ref>DOI:10.2174/157015909790031157</ref> As a consequence, the MMP family has emerged as an attractive pharmaceutical target. | ||
Blocking MMP gene transcription, proenzyme activation or active site-directed inhibitions are possible approaches for therapeutic intervention. | Blocking MMP gene transcription, proenzyme activation or active site-directed inhibitions are possible approaches for therapeutic intervention. | ||
==3D structures of MMP== | |||
[[Matrix metalloproteinase]] | |||
Latest revision as of 01:03, 6 January 2022
Endopeptidases involved in the degradation of the extracellular matrix
The matrix metalloproteinases (MMPs) are zinc- and calcium dependent neutral endopeptidases involved in the degradation of the extracellular matrix and in tissue remodeling. Currently, approximately 27 MMPs are known. These have been grouped into subfamilies on the basis of their substrate specificity. Transcriptional regulation, zymogen activation and endogenous inhibitors control MMP activity under normal physiological conditions. Disturbance of this physiological balance may lead to an overexpression of MMPs followed by accelerated matrix degradation. The latter is associated with several pathologies including cancer cell invasion and metastasis, the loss of cartilage in osteoarthritis, rheumatoid arthritis, cardiovascular diseases, acute lung injury, chronic obstructive pulmonary disease, eye and skin diseases and periodontitis.[1] As a consequence, the MMP family has emerged as an attractive pharmaceutical target. Blocking MMP gene transcription, proenzyme activation or active site-directed inhibitions are possible approaches for therapeutic intervention.
3D structures of MMP
- ↑ Dong X, Song YN, Liu WG, Guo XL. Mmp-9, a potential target for cerebral ischemic treatment. Curr Neuropharmacol. 2009 Dec;7(4):269-75. doi: 10.2174/157015909790031157. PMID:20514206 doi:https://dx.doi.org/10.2174/157015909790031157
Proteopedia Page Contributors and Editors (what is this?)
Tzvia Selzer, Michal Harel, Ralf Stephan, Karsten Theis, Eran Hodis
